Drugs / A33
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00003543 | Jun 1998 → Aug 2002 | colorectal cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | A33 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00003543 ↗ |
| Known as | MOAB A33 | “humanized monoclonal antibody A33 (MOAB A33)” NCT00003543 ↗ |
| Modality | Monoclonal antibody | “humanized monoclonal antibody A33” NCT00003543 ↗ |
| Route | Intravenous | “Patients receive humanized MOAB A33 IV once a week for 14 weeks.” NCT00003543 ↗ |